|
End-of-day quote
Other OTC
|
||
| - USD | - |
|
| 05-21 | BioRegenx, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
| 04-16 | BioRegenx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| Market Cap | 3.4M 3.02M 2.82M 2.57M 4.85M 327M 4.89M 34.13M 13.22M 167M 12.77M 12.49M 536M | P/E 2024 |
-0.37x | P/E 2025 | -8.02x |
|---|---|---|---|---|---|
| Enterprise Value | 5.55M 4.93M 4.6M 4.19M 7.91M 533M 7.98M 55.65M 21.57M 273M 20.82M 20.37M 875M | EV / Sales 2024 |
4.58x | EV / Sales 2025 | 7.85x |
| Free-Float |
-
| Yield 2024 * |
-
| Yield 2025 | - |
| Manager | Title | Age | Since |
|---|---|---|---|
William Resides
CEO | Chief Executive Officer | 57 | 08/03/2024 |
Gary Hennerberg
SEC | Corporate Secretary | 69 | 08/03/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Richard Janney
BRD | Director/Board Member | 67 | 07/10/2024 |
Thomas Powers
BRD | Director/Board Member | 71 | 01/01/2012 |
William Resides
BRD | Director/Board Member | 57 | 08/03/2024 |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 2.34M 2.08M 1.94M 1.77M 3.34M 225M 3.37M 23.48M 9.1M 115M 8.79M 8.6M 369M | 1.85M 1.65M 1.54M 1.4M 2.64M 178M 2.67M 18.61M 7.21M 91.14M 6.96M 6.81M 292M |
| Net income | -23.05M -20.48M -19.12M -17.43M -32.86M -2.22B -33.17M -231M -89.65M -1.13B -86.56M -84.68M -3.64B | -1.54M -1.37M -1.28M -1.17M -2.2M -148M -2.22M -15.49M -6M -75.86M -5.8M -5.67M -243M |
| Net Debt | 2.11M 1.87M 1.75M 1.59M 3M 202M 3.03M 21.13M 8.19M 103M 7.91M 7.73M 332M | 2.15M 1.91M 1.78M 1.62M 3.06M 206M 3.09M 21.53M 8.34M 105M 8.05M 7.88M 338M |
Employees
-
Sector
-
Select your edition
All financial news and data tailored to specific country editions
















